Clinical Briefs in Primary Care – December 1, 2017
December 1, 2017
View Issues
-
CV Benefits of GLP-1RA Treatment in Type 2 Diabetes
Among the sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist classes of pharmacotherapy, there appears to be much more similarity than not. Should clinicians consider these salubrious cardiovascular effects a class effect? That is, should all members of the class be anticipated to experience similarly favorable cardiovascular outcomes?
-
Morphine in Dyspneic Acute Heart Failure
Based on recent data, clinicians should avoid morphine use in acute heart failure patients.
-
New Pharmacologic Direction for Parkinson’s Disease
Most clinicians are used to thinking about dopamine modulation when considering treatments for Parkinson’s disease. Unfortunately, none of the current treatments can be designated as disease-modifying, even though such treatment provides transient symptomatic relief.
-
Searching for Answers on Knee Osteoarthritis
Data consistently show that for knee osteoarthritis, weight loss is associated with symptomatic and functional improvement. The mechanism of this is incompletely understood, since weight loss has not been shown to affect the progressive degradation of cartilage typical of osteoarthritis.
-
Cardiorespiratory Fitness and Mortality
In both men and women in the United States, levels of cardiorespiratory fitness are inversely related to mortality. An encouraging epidemiologic study of women found that even brisk walking for about 30 minutes daily was associated with near maximal cardiovascular health benefits.
-
Considering Systemic Treatment for Atopic Dermatitis
A recent panel of eczema experts convened to provide advice about when clinicians should consider systemic treatment.